Get the Stockscreener App
465.08
0.48%
2.20
After Hours:
464.50
-0.58
-0.12%
Vertex Pharmaceuticals Inc stock is traded at $465.08, with a volume of 779.78K.
It is up +0.48% in the last 24 hours and down -6.21% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$462.88
Open:
$463.16
24h Volume:
779.78K
Relative Volume:
0.74
Market Cap:
$119.60B
Revenue:
$10.34B
Net Income/Loss:
$-489.90M
P/E Ratio:
34.89
EPS:
13.33
Net Cash Flow:
$-1.43B
1W Performance:
+1.10%
1M Performance:
-6.21%
6M Performance:
+11.26%
1Y Performance:
+33.74%
1-Day Range:
$461.41
$467.57
1-Week Range:
$456.07
$467.57
52-Week Range:
$341.85
$510.63
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Creative Planning Acquires 3,998 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Wall Street SWOT: Alpine Immune Sciences stock rides high on Vertex acquisition - Investing.com
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Vertex Pharmaceuticals Stock Price | VRTX Stock Quote, News, and History - Markets Insider
Q2 2025 Earnings Estimate for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Issued By Zacks Research - MarketBeat
Vertex Pharmaceuticals presents vanzacaftor/tezacaftor/deutivacaftor data - Yahoo Finance
Vertex Pharmaceuticals Inc. stock rises Thursday, still underperforms market - MarketWatch
Wall Street Analysts See Vertex (VRTX) as a Buy: Should You Invest? - Zacks Investment Research
Wall Street Analysts See Vertex (VRTX) as a Buy: Should You Invest? - Yahoo Finance
Wall Street Analysts See Vertex (VRTX) as a Buy: Should You Invest? - Nasdaq
Vertex to Pay $4.9 Billion for Kidney Disease Drug Developer - MSN
Vertex Announces Health Canada Acceptance of New Drug Submission for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-in-Class Triple Combination Treatment for Cystic Fibrosis - Yahoo Finance
Zacks Research Research Analysts Lift Earnings Estimates for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals presents vanzacaftor/tezacaftor/deutivacaftor data - TipRanks
Vertex Pharma (VRTX) Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA - StreetInsider.com
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference - Business Wire
DE Burlo Group Inc. Raises Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Receives Health Canada Marketing Authorization for Sickle Cell Disease Treatment - MarketWatch
Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia - Quantisnow
Vertex granted Marketing Authorization in Canada for Casgevy - TipRanks
Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia - Canada NewsWire
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now? - Yahoo Finance
Lonza to produce Casgevy for Vertex - The Pharma Letter
Lonza to Manufacture Commercial Supply of Vertex’s Sickle Cell Disease Gene-Edited Cell Therapy, CASGEVY - BioPharm International
Vertex Lifts Revenue Outlook on Growth of Cystic Fibrosis Drugs - MSN
Pain Meds, Cell Therapies & More: Vertex Pharma CEO Talks About What’s Next After Cystic Fibrosis - MedCity News
Lonza, Vertex Sign Long-Term Commercial Supply Pact For CASGEVY - Contract Pharma
Vertex taps Lonza to help produce global supply of cutting-edge CRISPR therapy Casgevy - FiercePharma
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Bank of Montreal Can - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Xponance Inc. Has $22.36 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Brokerages Set Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Target Price at $486.36 - MarketBeat
Fidelis Capital Partners LLC Increases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
The Best Biotech Stock to Invest $1,000 in Right Now - The Motley Fool
Skandinaviska Enskilda Banken AB publ Sells 46,090 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Suit Highlights Issues For Pharma Fertility Support - Law360
The best biotech plays outside the GLP-1 weight-loss market - Yahoo Finance
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by MRP Capital Investments LLC - Defense World
Demystifying Vertex Pharmaceuticals: Insights From 16 Analyst Reviews - Benzinga
Richardson Financial Services Inc. Boosts Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - Defense World
Vertex Pharmaceuticals, Inc. [VRTX] Shares Fall -1.48 % on Wednesday - Knox Daily
Market Insight: Vertex Pharmaceuticals, Inc. (VRTX)’s Notable Drop, Closing at 474.16 - The Dwinnex
Delaney Dennis R Buys 1,627 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - Defense World
Advancing independent research in cystic fibrosis - Vertex Newsroom
Axxcess Wealth Management LLC Boosts Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - Defense World
Oppenheimer Asset Management Inc. Sells 7,170 Shares of Vertex, Inc. (NASDAQ:VERX) - Defense World
Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Looking Into Vertex Pharmaceuticals's Recent Short Interest - Benzinga
Sickle Cell Gene Therapies Reach Patients, Moderna Cuts, Obesity Pill Race and ESMO 2024 - BioSpace
Vanguard Personalized Indexing Management LLC Buys 4,470 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030 - The Motley Fool
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vertex Pharmaceuticals Inc Stock (VRTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bhatia Sangeeta N. | Director |
Aug 30 '24 |
Option Exercise |
152.74 |
646 |
98,670 |
5,081 |
| Bhatia Sangeeta N. | Director |
Aug 30 '24 |
Sale |
500.00 |
646 |
323,000 |
4,435 |
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):